Acknowledgments

We thank Clemens Dasenbrock (Hannover, Germany) for supervising the in vivo experiments and Volker Rehse (Hannover, Germany) for performing them. Furthermore, we thank Christian Scheler, Proteome Factory (Berlin, Germany) for performance of the two dimensional gel-electrophoresis and protein identification by MALDI-MS.

Footnotes

  The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by the "Sächsische Aufbaubank" (Dresden/Germany) Project 6261, and the Fraunhofer-Society (München/Germany).

² To whom requests for reprints should be addressed, at RESprotect, Fiedlerstr. 34, D-01307 Dresden, Germany. Phone: +493514503201; Fax: +493514503210; E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

³ The abbreviations used are: BVDU, (E)-5-(2-bromovinyl)-2'-deoxyuridine; DOX, doxorubicin; MMC, mitomycin C; MXA, mitoxantrone; MALDI-MS, matrix-assisted laser desorption/ionization mass spectrometry; HOPI, Hoechst 33258/propidium iodide; DMBA, dimethylbenzanthrazene; CGH, comparative genome hybridization; ROS, reactive oxygen species.

⁴ Two-dimensional gel electrophoresis and MALDI-MS were performed by Proteome Factory (Berlin, Germany, http://www.proteomefactory.com).

⁵ R. Fahrig, J-C. Heinrich, F. Wilfert, C. Praha, D. Sonntag, unpublished observations.

Received 5/12/03. Accepted 7/14/03.

References

1. Schimke R. T. Gene amplification, drug resistance, and cancer. Cancer Res., 44: 1735-1742, 1984.
2. Belinsky M., Jaiswal A. K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev., 12: 103-117, 1993.
3. Shin H. J., Lee J. S., Hong W. K., Shin D. M. Study of multidrug resistance (mdr1) gene in non-small-cell lung cancer. Anticancer Res., 12: 367-370, 1992.
4. Fahrig R., Steinkamp-Zucht A. Induction or suppression of SV40 amplification by genotoxic carcinogens, non-genotoxic carcinogens or tumor promoters. Mutat. Res., 356: 217-224, 1996.
5. Fahrig R. Anti-recombinogenic and convertible co-mutagenic effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted pyrimidine nucleoside analogs in S. cerevisiae MP1. Mutat. Res., 372: 133-139, 1996.
6. Fahrig R., Steinkamp-Zucht A., Schaefer A. Prevention of adriamycin-induced mdr1 gene amplification and expression in mouse leukemia cells by simultaneous treatment with the anti-recombinogen bromovinyldeoxyuridine. Anticancer Drug Des., 15: 307-312, 2000.
7. Bromberg J. F., Wrzeszczynska M. H., Devgan G., Zhao Y., Pestell R. G., Albanese C., Darnell J. E., Jr. Stat3 as an oncogene. Cell, 98: 295-303, 1999.
8. Weitzman J. B., Fiette L., Matsuo K., Yaniv M. JunD protects cells from p53-dependent senescence and apoptosis. Mol. Cell, 6: 1109-1119, 2000.
9. Wakusawa S., Nakamura S., Miyamoto K. Establishment by adriamycin exposure of multidrug-resistant rat ascites hepatoma AH130 cells showing low DT-diaphorase activity and high cross resistance to mitomycins. Jpn. J. Cancer Res., 88: 88-96, 1997.
10. Grusch M., Fritzer-Szekeres M., Fuhrmann G., Rosenberger G., Luxbacher C., Elford H. L., Smid K., Peters G. J., Szekeres T., Krupitza G. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. Exp. Hematol., 29: 623-632, 2001.
11. Grusch M., Polgar D., Gfatter S., Leuhuber K., Huettenbrenner S., Leisser C., Fuhrmann G., Kassie F., Steinkellner H., Smid K., Peters G. J., Jayaram H. N., Klepal W., Szekeres T., Knasmuller S., Krupitza G. Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ., 9: 169-178, 2002.
12. Russo J., Gusterson B. A., Rogers A. E., Russo I. H., Wellings S. R., van Zwieten M. J. Comparative study of human and rat mammary tumorigenesis. Lab. Investig., 62: 244-278, 1990.
13. Sambrook J., Russell D. W. Ed. 3 . Molecular Cloning, Vol. 1–3: Cold Spring Harbor Laboratory Press Cold Spring Harbor, New York 2001.
14. Pagano M., Draetta G., Jansen-Durr P. Association of cdk2 kinase with the transcription factor E2F during S phase. Science (Wash. DC), 255: 1144-1147, 1992.
15. Kappler R., Schlegel J., Romanakis K., Mennel H-D., Scherthan H. Comparative genomic in situ hybridization discloses chromosomal copy number changes in a transplanted brain tumor line of the rat (Rattus norvegicus). Mamm. Genome, 9: 193-197, 1998.
16. Hodnick W. F., Sartorelli A. C. Measurement of dicumarol-sensitive NADPH: (menadione-cytochrome c) oxidoreductase activity results in an artifactual assay of DT-diaphorase in cell sonicates. Anal. Biochem., 252: 165-168, 1997.
17. Haber D. A., Beverley S. M., Kiely M. L., Schimke R. T. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J. Biol. Chem., 256: 9501-9510, 1981.
18. Desgranges C., Razaka G., D., F., Bricaud H., Herdewijn P., de Clercq E. Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo. Nucleic Acids Res., 12: 2081-2090, 1984.
19. Kallioniemi A., Kallioniemi O-P., Sudar D., Rutovitz D., Gray J. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash. DC), 258: 818-821, 1992.
20. Godbout R., Squire J. Amplification of a DEAD box protein gene in retinoblastoma cell lines. Proc. Natl. Acad. Sci. USA, 90: 7578-7582, 1993.
21. Squire J. A., Thorner P. S., Weitzman S., Maggi J. D., Dirks P., Doyle J., Hale M., Godbout R. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene, 10: 1417-1422, 1995.
22. Hoege C., Pfander B., Moldovan G. L., Pyrowolakis G., Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature (Lond.), 419: 135-141, 2002.
23. Hofmann R. M., Pickart C. M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell, 96: 645-653, 1999.
24. Fan Z., Beresford P. J., Zhang D., Xu Z., Novina C. D., Yoshida A., Pommier Y., Lieberman J. Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat. Immunol., 4: 145-153, 2003.
25. Basra J., Wolf C. R., Brown J. R., Patterson L. H. Evidence for human liver mediated free-radical formation by doxorubicin and mitozantrone. Anticancer Drug Des., 1: 45-52, 1985.
26. Dinkova-Kostova A. T., Talalay P. Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic. Biol. Med., 29: 231-240, 2000.
27. Hamlin J. L., Chi M. The mammalian dihydrofolate reductase locus. Biochim. Biophys. Acta, 1087: 107-125, 1990.
28. Kashani-Sabet M., Rossi J. J., Lu Y., Ma J. X., Chen J., Miyachi H., Scanlon K. J. Detection of drug resistance in human tumor by in vitro enzymatic amplification. Cancer Res., 48: 5775-5778, 1988.
29. Buettner R., Mora L. B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res., 8: 945-954, 2002.
30. Niu G., Shain K. H., Huang M., Ravi R., Bedi A., Dalton W. S., Jove R., Yu H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res., 61: 3276-3280, 2001.
31. Geng Y., D’Souza S., Xin H., Walter S., Choubey D. p202 levels are negatively regulated by serum growth factors. Cell Growth Differ., 11: 475-483, 2000.